Brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AcelRx Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.20). AcelRx Pharmaceuticals reported earnings of ($0.21) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.8%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 1st.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.14) to ($0.98). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.06) per share, with EPS estimates ranging from ($1.07) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover AcelRx Pharmaceuticals.
ACRX has been the subject of a number of analyst reports. ValuEngine downgraded AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Roth Capital set a $8.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 12th. Jefferies Group downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Finally, Royal Bank of Canada reduced their target price on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. AcelRx Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $6.18.
In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $1.90 per share, with a total value of $57,000.00. Following the purchase, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 28.10% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals during the 3rd quarter worth approximately $138,000. Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals during the 3rd quarter worth approximately $460,000. Virtu KCG Holdings LLC raised its stake in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter worth approximately $530,000. 13.70% of the stock is owned by institutional investors and hedge funds.
Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded up $0.07 during trading hours on Friday, reaching $2.20. The company’s stock had a trading volume of 263,034 shares, compared to its average volume of 539,215. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75. The firm has a market capitalization of $110.74, a P/E ratio of -1.96 and a beta of 2.96. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect AcelRx Pharmaceuticals Inc (ACRX) Will Post Earnings of -$0.22 Per Share” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/09/zacks-brokerages-expect-acelrx-pharmaceuticals-inc-acrx-will-post-earnings-of-0-22-per-share.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.